Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory biomarker study of immunecheckpoint inhibitors using tumor tissue and peripheral blood

Next Previous
X
Search
Trial Profile

An exploratory biomarker study of immunecheckpoint inhibitors using tumor tissue and peripheral blood

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacodynamics

    • Most Recent Events

    • 18 Oct 2021 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2021 Results of post hoc analysis of prospective biomarker study (n=68) assessing impacts on the efficacy of PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 TPS greater than equal to 50, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
    • 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top